Fig. 2

Effects of Ki16425 on motor disability and spinal demyelination during EAE^low. A, B Following immunization, neurological symptoms in sham, EAE^low, and EAE^low + Ki16425 (15 and 30 mg/kg) groups were recorded daily (A) and scores from days 9–20 were summed (B). C, D At 19–20 days after immunization, lumbar spinal cords (n = 3) were obtained from each group and their lysates were analyzed by Western blot to determine protein expression levels of LPAR1 (C) and LPAR3 (D) followed by quantification. E, F At 19–20 days after immunization, cryosections (n = 3 per spinal cord) of lumbar spinal cords (n = 3 per group) were stained with LFB (left panel in E) and quantified (F). G Lysates from lumbar spinal cords were analyzed by Western blot to determine protein expression levels of MBP followed by quantification (G). H At 19–20 days after immunization, Ki16425 treatment was withdrawn. Bars = 100 µm. Data are expressed as mean scores of motor disability, demyelination score, or protein expression ± SEM (ANOVA test; ^#p < 0.05 and ^##p < 0.01 versus sham group; *p < 0.05 and **p < 0.01 versus EAE^low group)